UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~December 1831, ~~2023~~2024

MEDICALE CORP.

(Exact name of registrant as specified in its charter)

Nevada

333-250025

98-1556944

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

9314 Forest Hill Blvd #929

Wellington, FL 33411

(Address of Principal Executive Offices)

(407) 245-7339

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒☐

Item 4.01. Change in Registrant’s Certifying Accountant.

(a) Dismissal of Former Independent Registered Public Accounting Firm

On ~~October~~December 1831, ~~2023~~2024, the ~~Board~~ Board of Directors of Medicale Corp. (the “Company”) ~~was informed that Gries & Associates, LLC (“Gries & Associates”) had sold its business to GreenGrowth CPAs (“GreenGrowth”) and subsequently~~ approved the dismissal of ~~Gries~~GreenGrowth &CPAs ~~Associates, LLC~~ (“~~Gries & Associates~~Greengrowth”) as the Company’s independent registered public accounting firm, effective immediately.

~~Gries & Associates~~Greengrowth’s ~~reports~~ reports on the Company’s financial statements as of ~~June~~and for the year ended September 30, ~~2023~~2023contained ~~contained~~ no adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except to indicate that there is ~~was substantial~~ doubt ~~about~~ ~~the~~as ~~Company’s~~to their ability to continue as a going concern.

In connection with the audits of the Company's consolidated financial statements for the fiscal years ended September 30, 2023, and in the subsequent interim period through June 30, ~~2023~~2024, there were no disagreements with ~~Gries &~~Greengrowthon ~~Associates on~~ any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of ~~Gries & Associates~~Greengrowth, would have caused ~~Gries & Associates to~~ Greengrowthto make reference to the matter in their report. There were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K) during the fiscal year ended September 30, 2023, or in the subsequent interim period through June 30, ~~2023~~2024.

In accordance with Item 304(a)(3) of Regulation S-K, on ~~October~~December 1831, ~~2023~~2024, the Company provided ~~Gries~~Greengrowthwith ~~& Associates with~~ a copy of the foregoing disclosures and requested that ~~Gries~~Greengrowthprovide ~~& Associates provide~~ a letter addressed to the SEC stating whether it agrees with such disclosures. A copy of ~~Gries & Associates~~Greengrowth’~~s letter~~sletter dated ~~October~~December 2331, 2024is ~~2023 is~~ filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) Appointment of New Independent Registered Public Accounting Firm

On ~~October~~December 2331, ~~2023~~2024, the ~~Board~~ Board of Directors of the Company approved the appointment of ~~GreenGrowth~~Victor Mokuolu, CPA PLLC (“VMCPA”) as the Company’s new independent registered public accounting firm for the fiscal year ending September 30, ~~2023~~2024. During the Company’s two most recent fiscal years September 30, 2022 and 2021, and in the subsequent interim period through ~~June~~May 305, 2023, neither the Company nor anyone acting on its behalf consulted with ~~Gries~~VMCPAwith ~~& Associates with~~ respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the consolidated financial statements of the Company, and no written report or oral advice was provided by ~~Gries~~VMCPAto ~~& Associates to~~ the Company that ~~Gries~~VMCPAconcluded ~~& Associates concluded~~ was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of either a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
16.1		Letter from ~~Gries~~GreenGrowth ~~& Associates~~CPAs, ~~LLC,~~ dated ~~October~~December 2331, ~~2023~~2024
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Medicale Corp.
Date: December 8, 2023	By:	/s/ Chen Zu De
Date: December 31, 2024	By:	/s/ Chen Zu De
	Name:	Chen Zu De
	Title:	Chief Executive Officer Chief Financial Officer

Filing Compare · Medicale Corp.